VK2735 showed a placebo-adjusted mean weight loss of up to 6.8% over 28 days and an 8.2% weight loss from baseline. How clinically significant is this level of weight reduction for patients with obesity, and how does it compare with other GLP-1/GIP co-agonists on the market?

The oral VK2735 showed a mild GI-related adverse event profile at doses up to 100 mg. Given the frequency of GI side effects in weight-loss medications, how encouraging are these safety findings, and what might this mean for patients' long-term adherence to VK2735 therapy?

In the VENTURE Phase 2 study, subcutaneous VK2735 demonstrated durability and weight maintenance up to seven weeks after the last dose. Could this mean that monthly dosing might be a viable option for some patients? What are the advantages of such an approach?

VK2735 works as a GLP-1 and GIP co-agonist. Can you discuss how this dual mechanism might enhance weight loss and metabolic outcomes compared to single agonist therapies, and what potential it has to affect other metabolic markers in obese patients?

The Phase 2 VENTURE study indicated a reduction in pre-diabetic patients transitioning to diabetes. How important are these findings in the broader context of metabolic health, and could VK2735 have applications beyond weight loss, such as in prediabetes or type 2 diabetes prevention?

The study suggests that prolonged treatment with VK2735 might lead to further reductions in body weight. What are the implications of this finding for obesity management, and how might it shape the development of future treatment plans and dosing schedules for VK2735?

With obesity pharmacotherapy rapidly evolving, where do you see VK2735 fitting into the treatment landscape if approved? How could it complement or compete with existing medications for obesity and metabolic disorders?

Viking Therapeutics plans to meet with the FDA to discuss VK2735's clinical path. What are the key considerations for the FDA in evaluating the therapy, and what data might be needed in future studies to further support VK2735's efficacy and safety in long-term obesity management?